Annamycin Pancreatic Cancer Data

Moleculin to Showcase New Annamycin Data at Major Scientific Conferences

Moleculin (MBRX) is set to showcase new data on its lead drug candidate, Annamycin (naxtarubicin), at the AACR Conference on Pancreatic Cancer and Two European Scientific Meetings. Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer. These presentations aim to clarify the development of Annamycan in hard-to-treat cancers. Moleculin's lead program, AnnAraC, is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML), and the ongoing MIRACLE trial evaluating AnnARAC in patients with relapsed/refractory AML.